Abbott has agreed to pay $385 million to resolve investigations and lawsuits related to its 2022 recall of powdered infant formula from its Sturgis, Michigan facility. The settlement does not imply any fault or liability, and the US government has closed its criminal investigation. Tests showed no unopened Abbott formula tested positive for Cronobacter sakazakii, a bacterium linked to infant illnesses. The CDC found no definitive link between the Sturgis plant and the reported cases, emphasizing contamination often occurs in homes. Abbott remains committed to product safety and serving families.
Abbott Laboratories (ABT) trades at USD 103.21 on Pluang as of Sep 14, 2026 23:01 WIB, showing a 1.23% gain for the day. The company’s market capitalization stands at $176.41 billion, reflecting its significant presence in the health sector. This trading performance comes following Abbott’s agreement to pay $385 million to resolve claims related to its 2022 infant formula recall, as detailed in the news.
Abbott Laboratories announced plans to spin off its Nutrition division to concentrate on higher-growth areas like diagnostics, medical devices, and pharmaceuticals. The company reported a 14.5% increase in Q3 revenue to $13.01 billion, driven mainly ...
Abbott Laboratories reported Q3 2026 results with adjusted earnings per share of $1.42, matching estimates, and revenue of $13.01 billion, slightly above expectations. Despite 14.5% sales growth, the company lowered its 2026 sales growth forecast due...
Abbott posted a 14.5% increase in reported sales and 7.0% comparable sales growth for Q3 2026, with GAAP diluted EPS of $0.53 and adjusted EPS of $1.42. The company expanded its portfolio with FDA approvals for innovative products like the Libre Duo ...
Abbott announced plans to separate its Nutrition business into a standalone, publicly traded company by the end of 2027. The new Nutrition company will focus on the growing healthy nutrition market with $8.5 billion in annual sales and iconic brands ...
